The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
PIV
TNBC
chemotherapy
pan-immune-inflammation value
prognostic biomarker
triple-negative breast cancer
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
12
2022
accepted:
06
03
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
Advanced triple-negative breast cancer (aTNBC) has a poor prognosis; thus, there is a need to identify novel biomarkers to guide future research and improve clinical outcomes. We tested the prognostic ability of an emerging, complete blood count (CBC)-based inflammatory biomarker, the pan-immune-inflammation value (PIV), in patients with aTNBC treated with first-line, platinum-based chemotherapy. This was a retrospective, monocentric, observational study. We included consecutive aTNBC patients treated with platinum-based, first-line chemotherapy at our Institution, and for whom baseline (C1) CBC data were available. We collected CBC data early on-treatment, when available. PIV was calculated as: (neutrophil count × platelet count × monocyte count)/lymphocyte count. Patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC) were included in a control, non-TNBC cohort. A total of 78 aTNBC patients were included. When evaluated as a continuous variable, PIV-C1 was associated with worse overall survival (OS; PIV has a promising prognostic discrimination ability in aTNBC patients treated with first-line, platinum-based chemotherapy. Both baseline and early on-treatment PIV are associated with clinical outcomes and may be exploited for creating PIV-based risk classifiers if further validated.
Sections du résumé
Background
UNASSIGNED
Advanced triple-negative breast cancer (aTNBC) has a poor prognosis; thus, there is a need to identify novel biomarkers to guide future research and improve clinical outcomes.
Objectives
UNASSIGNED
We tested the prognostic ability of an emerging, complete blood count (CBC)-based inflammatory biomarker, the pan-immune-inflammation value (PIV), in patients with aTNBC treated with first-line, platinum-based chemotherapy.
Design
UNASSIGNED
This was a retrospective, monocentric, observational study.
Methods
UNASSIGNED
We included consecutive aTNBC patients treated with platinum-based, first-line chemotherapy at our Institution, and for whom baseline (C1) CBC data were available. We collected CBC data early on-treatment, when available. PIV was calculated as: (neutrophil count × platelet count × monocyte count)/lymphocyte count. Patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC) were included in a control, non-TNBC cohort.
Results
UNASSIGNED
A total of 78 aTNBC patients were included. When evaluated as a continuous variable, PIV-C1 was associated with worse overall survival (OS;
Conclusion
UNASSIGNED
PIV has a promising prognostic discrimination ability in aTNBC patients treated with first-line, platinum-based chemotherapy. Both baseline and early on-treatment PIV are associated with clinical outcomes and may be exploited for creating PIV-based risk classifiers if further validated.
Identifiants
pubmed: 37063779
doi: 10.1177/17588359231165978
pii: 10.1177_17588359231165978
pmc: PMC10102956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359231165978Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Ann Oncol. 2021 Dec;32(12):1475-1495
pubmed: 34678411
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Immunity. 2022 Jan 11;55(1):31-55
pubmed: 35021057
Clin Exp Rheumatol. 2021 Mar-Apr;39 Suppl 129(2):88-93
pubmed: 33200738
Eur J Cancer. 2021 Jun;150:155-167
pubmed: 33901794
Lancet Oncol. 2020 Jan;21(1):44-59
pubmed: 31786121
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1593-1596
pubmed: 35462426
Breast Cancer Res. 2017 Jan 5;19(1):2
pubmed: 28057046
Breast Cancer Res Treat. 2017 Sep;165(2):365-373
pubmed: 28616768
Target Oncol. 2021 Jul;16(4):529-536
pubmed: 34076798
Sci Rep. 2018 Jun 7;8(1):8703
pubmed: 29880896
Ther Adv Med Oncol. 2022 Mar 8;14:17588359221079123
pubmed: 35281350
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113
pubmed: 34754128
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Clin Breast Cancer. 2023 Apr;23(3):e151-e162
pubmed: 36599769
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Front Oncol. 2020 Apr 21;10:580
pubmed: 32373539
Sci Rep. 2021 Jul 19;11(1):14662
pubmed: 34282214
Cancers (Basel). 2021 Apr 19;13(8):
pubmed: 33921727
BMC Cancer. 2019 Nov 8;19(1):1065
pubmed: 31703646
J Pediatr Endocrinol Metab. 2022 Oct 27;35(12):1481-1486
pubmed: 36284505
Lancet Oncol. 2021 Apr;22(4):499-511
pubmed: 33676601
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Eur J Clin Invest. 2023 Jan;53(1):e13872
pubmed: 36097823
ESMO Open. 2019 Feb 27;4(1):e000457
pubmed: 30964126
Br J Cancer. 2020 Aug;123(3):403-409
pubmed: 32424148
Biomedicines. 2018 Feb 11;6(1):
pubmed: 29439457